Fast-Tracking Psychedelics Research
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Fast-Tracking Psychedelics Research” inside PodZeus.
This episode of The Brian Lehrer Show explores the implications of President Trump's recent executive order to accelerate research into psychedelic drugs like LSD, MDMA, psilocybin, and ibogaine for treating mental health conditions such as PTSD and opioid addiction. The discussion centers on the controversial role of podcaster Joe Rogan in influencing the policy shift, with Rogan claiming he sent data to the president showing ibogaine's potential to cure opioid addiction in over 90% of cases after two doses. However, Dr. Frederick Barrett of Johns Hopkins University clarifies that while these compounds show promise, especially ibogaine’s unique interaction with multiple brain systems including the opioid system, current evidence is largely anecdotal and lacks rigorous clinical validation. Barrett emphasizes the serious cardiotoxic risks associated with ibogaine, which have historically blocked U.S. research, and stresses the need for controlled, double-blind trials to assess real efficacy and safety. The episode also addresses concerns about 'true believer' bias in psychedelic research, the dangers of self-medication, and the historical context of psychedelic use in unregulated settings, while underscoring the importance of scientific rigor and patient safety in advancing this frontier of mental health treatment.
President Trump's executive order aims to streamline FDA approval for clinical trials of psychedelics, not to legalize them for recreational use.
Ibogaine shows potential for treating opioid addiction but carries significant cardiotoxic risks, requiring careful monitoring in clinical settings.
Current claims about psychedelic effectiveness are largely based on anecdotal reports; rigorous double-blind studies are essential for validation.
Psychedelic research must balance hope with scientific objectivity to avoid bias and ensure patient safety.
The 'consciousness' aspect of the Johns Hopkins center reflects an aspirational goal to understand how psychedelics may reveal deeper aspects of human awareness, though this remains scientifically unproven.
Introduction to Psychedelic Research and the Presidential Announcement
Brian Lehrer introduces the episode's focus on psychedelics as a potential tool for treating mental health conditions, highlighting President Trump's executive order to ease research into LSD, MDMA, psilocybin, and ibogaine, particularly for PTSD and addiction.
Joe Rogan's Influence and the Ibogaine Claim
“With two doses, it's more than 90%. I sent him that information. The text message came back, sounds great. Do you want FDA approval? Let's do it. It was literally that quick.”
Understanding Ibogaine: Science, Risks, and Mechanisms
Dr. Frederick Barrett explains ibogaine’s unique pharmacological profile, its interaction with multiple brain systems including the opioid system, and the serious cardiotoxicity that has hindered U.S. research.
The Need for Rigorous Clinical Trials
“None of the psychedelics that we're studying right now are approved as medicine. And so certainly they shouldn't be recommended for the treatment of substance use disorder, depression, trauma or anything else yet.”
Historical Context, Research Integrity, and the Future of Consciousness Studies
The episode reflects on the flawed early research of the 1950s–70s, addresses concerns about researcher bias, and explores the aspirational scientific goal of understanding consciousness through psychedelic research.
“None of the psychedelics that we're studying right now are approved as medicine. And so certainly they shouldn't be recommended for the treatment of substance use disorder, depression, trauma or anything else yet.”
“With two doses, it's more than 90%. I sent him that information. The text message came back, sounds great. Do you want FDA approval? Let's do it. It was literally that quick.”
“Psychedelics represent such powerful modulators of consciousness. I think when people say that psychedelics affect consciousness, they mean that maybe they reveal some aspect of an individual's consciousness to themselves that they may not have seen before.”
Host
Guest
Frederick Barrett
person
Ibogaine
product
Post-Traumatic Stress Disorder
other
Joe Rogan
person
Opioid Epidemic
other
Johns Hopkins University
organization
President Trump
person
Center for Psychedelic and Consciousness Research
organization
Psilocybin
product
FDA
organization
How Gaza and Zionism Are Dividing Synagogues
The Brian Lehrer Show • 41m • 3/31/2026
Meet the New NYC Health Commissioner
The Brian Lehrer Show • 28m • 3/31/2026
A 'People's History' of the Mets
The Brian Lehrer Show • 19m • 3/31/2026
The Women Leading the Farmworker Movement
The Brian Lehrer Show • 19m • 3/31/2026
Albany Budget Deadline Day
The Brian Lehrer Show • 13m • 4/1/2026
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Fast-Tracking Psychedelics Research” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime